Cargando…

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and trac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandra, Avinash, Valkimadi, Polytimi‐Eleni, Pagano, Gennaro, Cousins, Oliver, Dervenoulas, George, Politis, Marios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864887/ https://www.ncbi.nlm.nih.gov/pubmed/31520513 http://dx.doi.org/10.1002/hbm.24782

Ejemplares similares

Neuroimaging in Lewy body dementia
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment
por: Chandra, Avinash, et al.
Publicado: (2018)

Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients
por: Polychronis, Sotirios, et al.
Publicado: (2019)

Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge
por: Cousins, Oliver, et al.
Publicado: (2023)

Current status of PET imaging in Huntington’s disease
por: Pagano, Gennaro, et al.
Publicado: (2016)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
por: Ismail, Rola, et al.
Publicado: (2020)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Dementia spectrum disorders: lessons learnt from decades with PET research
por: Wilson, Heather, et al.
Publicado: (2019)

Posterior Circulation Ischemic Stroke Secondary to High-Grade Glioma: A Rare Case Report and Review of the Literature
por: Kasapas, Konstantinos, et al.
Publicado: (2020)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
por: Cisternas, Pablo, et al.
Publicado: (2019)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
por: Jiao, Fangyang, et al.
Publicado: (2023)

Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017)

Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer’s disease and mild cognitive impairment
por: Huang, Jie
Publicado: (2022)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

PET Imaging of Neuroinflammation in Alzheimer’s Disease
por: Zhou, Rong, et al.
Publicado: (2021)

Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice
por: Houben, Sarah, et al.
Publicado: (2020)

Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction
por: Hatashita, Shizuo, et al.
Publicado: (2013)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
por: Pagano, Gennaro, et al.
Publicado: (2017)

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
por: Laurent, Cyril, et al.
Publicado: (2018)

False Memory and Alzheimer's Disease Pathology in Patients with Amnestic Mild Cognitive Impairment: A Study with Amyloid PET
por: Choi, Eun-Ji, et al.
Publicado: (2021)

Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations
por: Melachroinou, Katerina, et al.
Publicado: (2016)

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
por: Chen, Yijun, et al.
Publicado: (2023)

Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease
por: Schulz, Jonathan, et al.
Publicado: (2018)

Cholinergic imaging in dementia spectrum disorders
por: Roy, Roman, et al.
Publicado: (2016)

Neuroimaging of Sleep Disturbances in Movement Disorders
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
por: Yousaf, Tayyabah, et al.
Publicado: (2019)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia
por: Ying, Chunwei, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
por: Wei, Hong-Chun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hvglri8tbs1qcu9p3p3o6774a